Key facts
- This page summarizes Richard van den Broek's Form 3 filing for Corvus Pharmaceuticals, Inc. (CRVS).
- 0 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 09 Apr 2025, 17:26.
Richard van den Broek - 08 Apr 2025 Form 3 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)
- Reporting relationship
- Director
- Issuer ticker
- CRVS
- Reported as of
- 08 Apr 2025
- Net transaction value
- $0
- SEC form
- 3
- Accepted by SEC
- 09 Apr 2025, 17:26:25 UTC
- Prior SEC filing
- 24 Jun 2024
- Next SEC filing
- 19 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Leiv Lea, as Attorney-in-Fact for Richard van den Broek
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard van den Broek filed Form 3 for Corvus Pharmaceuticals, Inc. (CRVS) on 09 Apr 2025.
Change
- Previous filing in this sequence was filed on 24 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Official SEC source
View source filing
Ownership activity is grounded in SEC Form 3 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRVS
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 160,000
- Date
- 08 Apr 2025
- Ownership
- See foonote
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Shares held by HSMR Advisors, LLC, of which the Reporting Person is the sole owner.
SEC remarks
Exhibit 24.1 - Power of Attorney